目前对阿尔茨海默病的诊断途径:在六个国家进行的横截面真实世界研究
Sophie Roth1, Nerida Burnie2, Ivonne Suridjan1
1Roche Diagnostics International Ltd, Rotkreuz, Switzerland.
Journal of Alzheimer's disease reports
|July 24, 2023
概括
认知投诉的诊断途径在全球范围内有所不同. 许多患者没有得到确定的诊断,这凸显了改善生物标志物使用和获得阿尔茨海默病 (AD) 等疾病检测的必要性.
科学领域:
- 神经学 神经学
- 神经科学是一个神经科学.
- 公共卫生 公共卫生
背景情况:
- 认知方面的投诉是咨询医生的常见原因.
- 这些投诉的诊断途径可以根据地理位置和医疗保健系统显著不同.
研究的目的:
- 调查和描述六个不同国家的认知投诉患者的诊断途径.
- 识别不同医疗保健提供者和不同地区的诊断方法和结果的差异.
主要方法:
- 一项现实世界的横截面研究分析了6,744名患者的图表提取数据.
- 数据来自中国,法国,德国,西班牙,英国和美国的医疗保健提供者.
- 分析包括症状表现,临床/认知测试的使用,生物标志物测试 (APOE,粉样蛋白PET,CSF) 和诊断率.
主要成果:
- 认知症状 (记忆/记忆障碍) 是最常见的 (89.86%),其次是身体/行为症状 (87.13%).
- 临床/认知测试被普遍使用 (>95%),迷你精神状态检查是最常见的 (79.0%).
- 只有52.1%的患者接受了诊断,最常见的是阿尔茨海默病 (AD). 影响诊断的因素包括提供者类型和地区,初级保健和中国/德国的比例较低. 粉样蛋白PET和CSF测试得到了充分利用,即使是专家.
结论:
- 在不同国家和提供者类型的AD诊断途径中存在显著的变化.
- 大约有45%的患者使用"观察和等待"方法进行治疗,这表明诊断缺口.
- 需要在使用先进的生物标志物测试 (粉样PET,CSF) 和解决测试能力和报销等障碍方面进行改进,以优化认知障碍的诊断和护理.
关键词:
阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.认知功能障碍 认知功能障碍痴呆症 痴呆症是一种痴呆症.诊断 诊断 诊断 诊断 诊断 诊断神经学 神经学 神经学神经心理测试 神经心理测试护理的标准 护理的标准调查和问卷调查和问卷调查.更多相关视频
08:29Symmetric Bihemispheric Postmortem Brain Cutting to Study Healthy and Pathological Brain Conditions in Humans
Published on: December 18, 2016
14.1K
09:38Generalized Psychophysiological Interaction PPI Analysis of Memory Related Connectivity in Individuals at Genetic Risk for Alzheimer's Disease
Published on: November 14, 2017
15.0K
相关概念视频
Alzheimer's Disease: Overview
525
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
525
Alzheimer's Disease: Treatment
219
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
219
Dementia
141
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
141
